A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations (Q41189315)

28 September 2017

1 reference

title

A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations (English)

1 reference

28 September 2017

S M Hart

1

1 reference

28 September 2017

E M Bailey

series ordinal

2

1 reference

28 September 2017

language of work or name

English

0 references

publication date

1 October 1996

1 reference

Annals of Pharmacotherapy

28 September 2017

published in

1 reference

28 September 2017

volume

30

1 reference

28 September 2017

issue

10

1 reference

28 September 2017

page(s)

1130-1140

1 reference

Piperacillin/Tazobactam: A New Beta-Lactam/Beta-Lactamase Inhibitor Combination

28 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Piperacillin/tazobactam: a critical review of the evolving clinical literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

New mechanisms of bacterial resistance to antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

The inhibition of beta-lactamases from gram-negative bacteria by clavulanic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

The beta-lactamases of gram-negative bacteria and their possible physiological role.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

The structure of β-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Comparative Inhibition of β-Lactamases by Novel β-Lactam Compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Clavulanic Acid, a Novel Inhibitor of β-Lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Diverse potential of beta-lactamase inhibitors to induce class I enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Clavulanate and beta-lactamase induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Turbidimetric and microscopic analysis of Bacteroides fragilis exposed to tazobactam and piperacillin alone and in combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Pharmacology of ticarcillin combined with clavulanic acid in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Penetration to peripheral human lymph of clavulanic acid and ticarcillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Concentrations of ticarcillin and clavulanic acid in human bone after prophylactic administration of 5.2 g of timentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Ticarcillin for treatment of serious infections with gram-negative bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Pharmacokinetics of ampicillin and sulbactam in patients undergoing heart surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Penetration of sulbactam-ampicillin and clavulanic acid-amoxicillin into the pelvic peritoneum

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Penetration of piperacillin-tazobactam into bronchial secretions after multiple doses to intensive care patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Bacterial meningitis in the United States, 1978 through 1981. The National Bacterial Meningitis Surveillance Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. The Bacterial Meningitis Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Management of infections caused by antibiotic-resistant Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Timentin in the treatment of nosocomial bronchopulmonary infections in intensive care units

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Comparison of the safety and efficacy of parenteral ticarcillin/clavulanate and clindamycin/gentamicin in serious intra-abdominal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

Activity of newer beta-lactam agents against clinical isolates of Bacteroides fragilis and other Bacteroides species

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001013

10.1177/106002809603001013

21 January 2018

Identifiers

DOI

1 reference

28 September 2017

1 reference